News and Announcements
OncoSil Medical CE Mark Update
- Published October 13, 2015 1:32PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
12th October 2015, ASX Announcement
OnoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to provide the following update on its Conformité Européenne (CE) Mark application for the Company’s OncoSilTM localised radiation treatment for cancer.
As previously advised (ASX announcement, 9 September 2015), OncoSil Medical was granted a Fast Track review by the European regulator to assess its CE Mark application for OcoSilTM in pancreatic and primary liver cancer (HCC).
OncoSil Medical now advises that the Fast Track Face-To-Face review phase has been completed, and it now awaits the final outcome of the review as the Notified Body continues to its assessment over the coming weeks. The Compnay was pleased with the review meeting and anticipates that the Notified Body will make a decision in respect of the CE Mark for OncoSilTM in November.
To read the full announcement, please click here.